10-K · July 13, 2026
Adagio Medical Holdings, Inc. continues to face challenges, reporting no revenue for Q1 2026 and an EPS of -0.31, which fell short of estimates. There was a significant focus on governance, including the successful…
Earnings analysis · 10-Q
ADGM earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q does not include the income statement, balance sheet, cash-flow statement, segment disclosures, or MD&A financial tables, so revenue, margins, EPS, cash flow, debt, liquidity, and working-capital…
Read full summary
The extracted 10-Q does not include the income statement, balance sheet, cash-flow statement, segment disclosures, or MD&A financial tables, so revenue, margins, EPS, cash flow, debt, liquidity, and working-capital trends cannot be quantified. The available disclosures remain materially negative: the company reported a $13.7 million six-month net loss and a $109.4 million accumulated deficit as of June 30, 2026, while expecting substantial losses and negative cash flows for the foreseeable future. Key updated or emphasized risks include going-concern financing uncertainty, FDA and tariff-related regulatory uncertainty, and a Nasdaq minimum-bid deficiency with a December 9, 2026 compliance deadline.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls deemed effective
Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026, with no material changes to internal control over financial reporting during the period.
-
No material legal proceedings
The company reported no legal proceedings that were currently expected to have a material adverse effect on its business, financial condition, or results of operations as of the filing dated August 11, 2026.
What to watch
-
Continuing losses and going-concern risk
The company incurred a net loss of $13.7 million for the six months ended June 30, 2026, compared with an accumulated deficit of $109.4 million as of that date. Management expects substantial losses and negative cash flows for the foreseeable future, creating substantial doubt about the company’s ability to continue as a going concern.
-
FDA and tariff uncertainty
The company disclosed political and regulatory uncertainty, including FDA workforce reductions that could delay reviews, as well as a Bureau of Industry and Security investigation into potential tariffs on medical devices manufactured outside the United States. These developments could increase costs or delay commercialization of the vCLAS platform.
-
Nasdaq minimum-bid deficiency
Nasdaq notified the company on June 12, 2026 that its common stock failed the Minimum Bid Price Requirement and granted an initial 180-calendar-day compliance period ending December 9, 2026. The company must generally maintain a bid price of at least $1.00 for 10 consecutive business days to regain compliance, or risk delisting and reduced financing access.
Management's outlook
No quantitative revenue or EPS outlook was provided in the extracted 10-Q text; outlook appears deferred to the earnings press release or call.
Earlier filings 4
10-Q · May 12, 2026
Adagio Medical reported a net loss of $7.0 million for Q1 2026, which is an improvement compared to a loss of $7.7 million in Q1 2025. Revenue remained at nil for both periods due to a pause in commercial activities,…
10-K · March 27, 2026
Adagio positions itself as a purpose-built medical device company targeting the underserved ventricular tachycardia (VT) market with its proprietary ULTA catheter platform; the company completed enrollment in its…
10-Q · August 14, 2025
Adagio reported Q2 2025 revenue of $0 and a diluted loss per share of $(0.35), an improvement versus the prior-year quarter’s diluted loss per share of $(7.35). Operating loss narrowed to $(4,717) in Q2 2025 from…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.